Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Ye Hu, Jiyue Gao, Meiling Wang, et al.
Cancer Management and Research (2021) Vol. Volume 13, pp. 5223-5237
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 267
Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
Ruoning Yang, Yueyi Li, Hang Wang, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 74
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Ying Li, Zhijun Zhan, Xuemin Yin, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 80
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer
Jamil Nehme, Sjors Maassen, Sara Bravaccini, et al.
The EMBO Journal (2025)
Open Access | Times Cited: 1
Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
Aiswarya Chaudhuri, Dulla Naveen Kumar, Deepa Dehari, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2661-2661
Open Access | Times Cited: 15
Extracellular Vesicles and Artificial Intelligence: Unique Weapons against Breast Cancer
Enrica Serretiello, Annafrancesca Smimmo, Andrea Ballini, et al.
Applied Sciences (2024) Vol. 14, Iss. 4, pp. 1639-1639
Open Access | Times Cited: 5
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Wen‐Ting Peng, Xi Jin, Xiao‐En Xu, et al.
Cancer Research (2023) Vol. 83, Iss. 10, pp. 1711-1724
Open Access | Times Cited: 11
CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis
Naema Nayyar, Magali de Sauvage, Jane Chuprin, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 2, pp. 420-435
Open Access | Times Cited: 11
Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications
Priya Mehta, Ranjit Kumar, Dhruv Kumar
3 Biotech (2025) Vol. 15, Iss. 1
Closed Access
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer
Dorian V. Ziegler, Kanishka Parashar, Lucía C. Leal-Esteban, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Targeting CDK4/6 in breast cancer
Anusha Shanabag, Jessica Armand, Eugene Son, et al.
Experimental & Molecular Medicine (2025)
Open Access
A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer
Yan Wang, Chen Zhang, Meng Xiao, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 79, pp. 103922-103922
Closed Access | Times Cited: 18
Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer
Xiaoyu Chen, Chengxia Shu, Wenqiang Li, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6729-6747
Closed Access | Times Cited: 16
Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway
Jing Wang, Jiaxin Zhang, Qinglong Ma, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 7, pp. 991-1005
Open Access | Times Cited: 9
Curcumin-induced antitumor effects on triple-negative breast cancer patient-derived xenograft tumor mice through inhibiting salt-induced kinase-3 protein
Tzu‐Chun Cheng, John Oliver Sayseng, Shih‐Hsin Tu, et al.
Journal of Food and Drug Analysis (2021) Vol. 29, Iss. 4, pp. 622-637
Open Access | Times Cited: 22
The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer
Melanie Kirkby, Alyanna Popatia, Jessie R. Lavoie, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4702-4702
Open Access | Times Cited: 8
Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis
Mirosława Püsküllüoğlu, Agnieszka Rudzińska, Renata Pacholczak‐Madej
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188991-188991
Open Access | Times Cited: 8
Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment
Mark Samuels, Chiara Cilibrasi, Panagiotis Papanastasopoulos, et al.
Biomolecules (2022) Vol. 12, Iss. 1, pp. 132-132
Open Access | Times Cited: 12
Co-targeting CDK 4/6 and C-MYC/STAT3/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand
Zhimin Lv, Amjad Ali, Na Wang, et al.
Journal of Inorganic Biochemistry (2024) Vol. 259, pp. 112661-112661
Open Access | Times Cited: 2
Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer
Yonglei Zhang, Long Zheng, Liangliang Ma, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 23, pp. 21186-21207
Closed Access | Times Cited: 2
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Melina Beykou, Mar Arias-García, Theodoros I. Roumeliotis, et al.
Scientific Data (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy
Yaseen Hussain, Haroon Khan, Waqas Alam, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-14
Open Access | Times Cited: 9
Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
Gamze Güney Eskiler, Zeynep Özman, Ayten Haciefendi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 5, pp. 1031-1041
Closed Access | Times Cited: 5
Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple‐negative breast cancer (TNBC)
Gaidaa M. Dogheim, Mohamed T. Amralla
Drug Development Research (2023) Vol. 84, Iss. 4, pp. 629-653
Closed Access | Times Cited: 5
Molecular targets and therapeutic strategies for triple-negative breast cancer
Yashasvi Bhat, M. R. Thrishna, Satarupa Banerjee
Molecular Biology Reports (2023) Vol. 50, Iss. 12, pp. 10535-10577
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top